Biotechnology - USA

Filter

Current filters:

USA

Popular Filters

1 to 25 of 181 results

Merck unit inks antibody drug conjugates deal with Sutro Biopharma

Merck unit inks antibody drug conjugates deal with Sutro Biopharma

18-09-2014

EMD Serono, a US subsidiary of Germany’s Merck KGaA has entered into a collaboration and license agreement…

BiotechnologyEMD SeronoLicensingMerck KGaAOncologyResearchUSA

Gilead’s simtuzumab fails in Ph II pancreatic cancer study

Gilead’s simtuzumab fails in Ph II pancreatic cancer study

17-09-2014

US biotech major Gilead Sciences has announced disappointing results from a Phase II study evaluating…

BiotechnologyGilead SciencesOncologyResearchsimtuzumabUSA

Dimension Therapeutics appoints Annalisa Jenkins as chief executive

Dimension Therapeutics appoints Annalisa Jenkins as chief executive

17-09-2014

Dimension Therapeutics, a US gene therapy company focused on rare diseases, has appointed Annalisa Jenkins…

BiotechnologyBoardroomDimension TheapeuticsDimension TherapeuticsUSA

FDA grants Breakthrough status for Eylea in diabetic retinopathy in patients with DME

FDA grants Breakthrough status for Eylea in diabetic retinopathy in patients with DME

16-09-2014

US biotech firm Regeneron Pharmaceuticals says that the US Food and Drug Administration has granted Eylea…

BayerBiotechnologyEyleaOphthalmicsRegeneron PharmaceuticalsRegulationUSA

SIGA Technologies files for Chapter 11 reorganization

SIGA Technologies files for Chapter 11 reorganization

16-09-2014

Biological warfare defense firm SIGA Technologies has filed a voluntary petition for relief under chapter…

Anti-viralsBiotechnologyFinancialLegalPharmAtheneSIGA TechnologiesTecovirimatUSA

FDA approves Baxter/Halozyme’s HyQvia

FDA approves Baxter/Halozyme’s HyQvia

14-09-2014

The US Food and Drug Administration on Friday approved Baxter International’s and Halozyme Therapeutics’…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

12-09-2014

US biotech firm Biogen Idec has reported data confirming its Plegridy gives provides treatment effects…

Biogen IdecBiotechnologyNeurologicalPlegridyResearchUSA

Strong and sustained efficacy reported for Tecfidera over five years

Strong and sustained efficacy reported for Tecfidera over five years

12-09-2014

Results from a five-year study with US biotech firm Biogen Idec’s Tecfidera show strong and sustained…

Biogen IdecBiotechnologyNeurologicalResearchTecfideraUSA

MabVax links with Memorial Sloan Kettering and Juno on anti-cancer therapeutics

MabVax links with Memorial Sloan Kettering and Juno on anti-cancer therapeutics

11-09-2014

Clinical stage oncology drug development company MabVax Therapeutics has entered agreements with Memorial…

BiotechnologyCancer therapeuticsChimeric antigen receptorMabVax TherapeuticsOncologyResearchUSA

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

09-09-2014

The recent US Food and Drug Administration and European Commission approval of HIV specialist ViiV Healthcare’s…

Anti-viralsAtriplaBiotechnologyGilead SciencesGlobalDataHIVMarkets & MarketingStribildTriumeqUSAViiV Healthcare

Hyperion terminates DaiPep277 program due to "misconduct"

08-09-2014

Shares of Hyperion Therapeutics’ plunged 11% to $24.61 in pre-market trading today, after the company…

Andromeda BiotechAndromeda GalaxyAstronomyBiotechnologyDiabetesDiaPep277HyperionHyperion TherapeuticsResearchUSA

Eisai divests US Zonegran rights to Concordia

Eisai divests US Zonegran rights to Concordia

07-09-2014

Japanese drugmaker Eisai (TYO: 4523) says its US subsidiary has entered into an agreement to divest its…

BiotechnologyConcordia PharmaceuticalsEisaiMergers & AcquisitionsNeurologicalUSAZonegran

FDA lifts partial clinical hold on OncoMed's ipafricept

05-09-2014

Shares of US biotech companies OncoMed Pharmaceuticals rose 5.6% to $17.68 on news that the US Food and…

BayerBiotechnologyipafriceptOncologyOncoMed PharmaceuticalsRegulationResearchUSA

US HHS contracts with Mapp Biopharmaceutical to develop Ebola drug

03-09-2014

The US Department of Health and Human Services has awarded a $25 million contract to Mapp Biopharmaceutical…

Anti-viralsBiotechnologyFinancialMapp BiopharmaceuticalResearchTropical diseasesUSAZMapp

FDA Breakthrough designation for ACADIA’s Nuplazid for Parkinson’s disease psychosis

FDA Breakthrough designation for ACADIA’s Nuplazid for Parkinson’s disease psychosis

03-09-2014

US biotech firm ACADIA Pharmaceuticals says that the US Food and Drug Administration has granted Breakthrough…

ACADIA PharmaceuticalsBiotechnologyNeurologicalNuplazidpimavanserinRegulationUSA

FDA priority review for Amgen’s ivabradine in CHF

FDA priority review for Amgen’s ivabradine in CHF

27-08-2014

The US Food and Drug Administration has granted priority review designation for US biotech giant Amgen’s…

AmgenBiotechnologyCardio-vascularivabradineRegulationServierUSA

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

26-08-2014

Ireland-headquartered biotech firm Alkermes has submitted a New Drug Application to the US Food and Drug…

AbilifyAlkermesaripiprazole lauroxilBiotechnologyNeurologicalRegulationUSA

ViaCyte gets $20 million in deal with Janssen

ViaCyte gets $20 million in deal with Janssen

22-08-2014

Privately held US regenerative medicine company ViaCyte has entered into a rights agreement with Janssen…

BiotechnologyDiabetesEndocrine systemFinancialJanssenJohnson & JohnsonLicensingUSAVC-01ViaCyte

1 to 25 of 181 results

Back to top